Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

EDIT

Editas Medicine Inc

Mar 13 • 04:00PM ET

1.37

Dollar change -0.14
Percentage change -9.27	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA BEAM BLUE SGMO VERV RARE PSTX CLLS QURE

| Held by: VTI IWM VXF IWN IBB DFAT SCHA VTWO VHT DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.88	Insider Own	0.91%	Shs Outstand	82.73M	Perf Week	-23.03%
Market Cap	113.68M	Forward P/E	-	EPS next Y	-1.06	Insider Trans	-3.30%	Shs Float	82.23M	Perf Month	16.10%
Income	-237.09M	PEG	-	EPS next Q	-0.56	Inst Own	62.52%	Short Float	16.74%	Perf Quarter	-38.57%
Sales	32.31M	P/S	3.52	EPS this Y	50.77%	Inst Trans	-6.86%	Short Ratio	3.21	Perf Half Y	-63.66%
Book/sh	1.62	P/B	0.84	EPS next Y	25.07%	ROA	-56.40%	Short Interest	13.77M	Perf Year	-84.78%
Cash/sh	3.25	P/C	0.42	EPS next 5Y	23.95%	ROE	-98.10%	52W Range	1.12 - 8.86	Perf YTD	7.87%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-1.48%	ROI	-153.31%	52W High	-84.54%	Beta	2.07
Dividend TTM	-	Quick Ratio	3.75	Sales past 5Y	96.99%	Gross Margin	82.02%	52W Low	22.32%	ATR (14)	0.27
Dividend Ex-Date	-	Current Ratio	3.75	EPS Y/Y TTM	-40.05%	Oper. Margin	-739.40%	RSI (14)	43.22	Volatility	12.15% 19.81%
Employees	246	Debt/Eq	0.26	Sales Y/Y TTM	-58.64%	Profit Margin	-733.74%	Recom	2.60	Target Price	3.78
Option/Short	Yes / Yes	LT Debt/Eq	0.15	EPS Q/Q	-138.92%	Payout	-	Rel Volume	0.48	Prev Close	1.51
Sales Surprise	2.85%	EPS Surprise	-45.73%	Sales Q/Q	-49.03%	Earnings	Mar 05 AMC	Avg Volume	4.29M	Price	1.37
SMA20	-23.85%	SMA50	-8.42%	SMA200	-57.17%	Trades		Volume	2,065,810	Change	-9.27%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-16-24	Downgrade	JP Morgan	Neutral → Underweight
Dec-13-24	Downgrade	Truist	Buy → Hold
Dec-13-24	Downgrade	Stifel	Buy → Hold	$11 → $3
Dec-13-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Dec-11-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$7 → $4
Nov-25-24	Downgrade	BofA Securities	Buy → Underperform	$13 → $1
Nov-06-24	Upgrade	Evercore ISI	In-line → Outperform
Nov-04-24	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-08-24	Upgrade	BofA Securities	Neutral → Buy	$13 → $15
May-09-24	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$7
Oct-24-23	Upgrade	Citigroup	Neutral → Buy	$11
Oct-18-23	Upgrade	JP Morgan	Underweight → Neutral	$8
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-29-23	Upgrade	Stifel	Hold → Buy	$9 → $17
Jun-12-23	Upgrade	Raymond James	Mkt Perform → Outperform	$17
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-13-22	Initiated	Citigroup	Neutral	$11
Dec-06-22	Resumed	Credit Suisse	Neutral	$13
Nov-18-22	Downgrade	Oppenheimer	Outperform → Perform	$28 → $12
Nov-18-22	Downgrade	Credit Suisse	Outperform → Neutral	$25 → $13

Show Previous Ratings

Mar-05-25 05:25PM	Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +16.48% -13.17%
04:19PM	Editas: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates (GlobeNewswire)
Feb-24-25 09:00AM	Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March (GlobeNewswire)
Jan-14-25 09:30AM	Editas Medicine Outlines 2025 Strategic Priorities and Milestones (TipRanks)
09:00AM	Loading…
Jan-13-25 09:00AM	Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities (GlobeNewswire) -7.94%
Jan-06-25 09:00AM	Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.72%
Dec-30-24 03:11PM	Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In? (Insider Monkey)
Dec-14-24 07:01AM	Editas Medicine price target lowered to $8 from $10 at Baird (TipRanks)
Dec-13-24 02:15PM	Brokerages downgrade gene editing company Editas to 'hold', shares slump 23% (Investing.com) -23.81%
01:26PM	Editas Medicine Reshapes Future with In Vivo Focus Amid Major Workforce Cuts (GuruFocus.com)
06:44AM	Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026 (Benzinga)
Dec-12-24 04:00PM	Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years (GlobeNewswire) -5.03%
12:37PM	Editas to lay off staff after search for sickle cell partner comes up empty (BioPharma Dive)
Dec-09-24 12:00PM	Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
11:30AM	Loading…
Dec-04-24 11:30AM	Why Is Editas (EDIT) Down 36.5% Since Last Earnings Report? (Zacks)
Nov-26-24 06:50AM	Editas Medicine downgraded to Underperform from Buy at BofA (TipRanks) -7.14%
Nov-06-24 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.13%
Nov-05-24 01:59PM	Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty (GuruFocus.com) +8.33%
Nov-04-24 08:40AM	Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:36AM	Editas: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Editas Medicine Announces Third Quarter 2024 Results and Business Updates (GlobeNewswire)
Oct-31-24 03:55AM	Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock? (Insider Monkey)
Oct-25-24 10:00AM	Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline (Zacks)
Oct-22-24 12:13PM	Editas and Genevant team up to develop gene editing therapies (Pharmaceutical Technology) -12.50%
07:15AM	Editas, changing course again, looks to partner lead CRISPR therapy (BioPharma Dive)
07:00AM	Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update (GlobeNewswire)
Oct-21-24 04:30PM	Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics (GlobeNewswire) +11.90%
Oct-18-24 04:01PM	Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept (GlobeNewswire)
Oct-17-24 05:01PM	State Street Corp's Strategic Reduction in Editas Medicine Inc Holdings (GuruFocus.com)
06:27AM	Loading…
Oct-05-24 06:27AM	Editas Medicine Secures $57M Deal for Gene-Editing Technology (TipRanks)
Oct-04-24 07:13PM	Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m (Pharmaceutical Technology) +5.62% -5.03%
07:33AM	Editas trades Vertex fees for upfront cash in DRI deal (BioPharma Dive)
Oct-03-24 06:00PM	Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust (GlobeNewswire)
Sep-06-24 11:31AM	Editas (EDIT) Down 17% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-28-24 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 09:33AM	Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down (Zacks)
03:39AM	Q2 2024 Editas Medicine Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-24 08:05AM	Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -12.18%
07:07AM	Editas: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces Second Quarter 2024 Results and Business Updates (GlobeNewswire)
Jul-31-24 07:00AM	Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update (GlobeNewswire)
Jul-17-24 11:30AM	3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition (InvestorPlace)
Jul-09-24 07:59AM	3 Profitable CRISPR Stocks Earning Analysts' Praise (InvestorPlace)
Jul-08-24 09:00AM	The 3 Best Gene Editing Stocks to Buy in July 2024 (InvestorPlace) +5.01%
Jun-29-24 08:40PM	Is Editas Medicine, Inc. (EDIT) One of the Best Biotech Penny Stocks to Buy Now? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-27-24 09:04AM	What Makes Editas Medicine, Inc. (EDIT) One of the Best Small-Cap Stocks with Highest Upside Potential? (Insider Monkey)
Jun-26-24 09:33PM	Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich (InvestorPlace)
04:36PM	Top 10 Small-Cap Stocks with Highest Upside Potential (Insider Monkey)
Jun-25-24 08:00AM	3 Gene Editing Stocks That Could Make Your Grandchildren Rich (InvestorPlace)
Jun-17-24 08:13AM	Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies (Zacks)
Jun-14-24 03:01AM	Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress (GlobeNewswire) -7.83%
03:00AM	Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress (GlobeNewswire)
Jun-07-24 11:30AM	Editas (EDIT) Down 2.3% Since Last Earnings Report: Can It Rebound? (Zacks)
May-22-24 07:05PM	EVP, Chief Financial Officer Erick Lucera Sells 22,337 Shares of Editas Medicine Inc (GuruFocus.com) +9.26%
May-14-24 07:01PM	Director Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc (GuruFocus.com) +5.63%
04:27PM	Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing (MT Newswires)
10:00AM	Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June (GlobeNewswire)
May-10-24 06:00AM	Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-09-24 03:38PM	Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript (Insider Monkey) +10.43%
01:12PM	1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5? (Motley Fool)
12:40PM	Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down (Zacks)
11:33AM	Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating (MT Newswires)
08:00AM	Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight (MT Newswires)
May-08-24 10:33PM	Q1 2024 Editas Medicine Inc Earnings Call (Thomson Reuters StreetEvents) -11.36%
11:55AM	EDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:25AM	Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:29AM	Editas: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces First Quarter 2024 Results and Business Updates (GlobeNewswire)
May-02-24 07:00AM	Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events (GlobeNewswire)
May-01-24 10:46AM	Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration (MT Newswires)
08:00AM	Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration (GlobeNewswire)
Apr-29-24 10:26AM	12 Under-the-Radar Stocks With Massive Upside for 2024 (Insider Monkey)
Apr-26-24 10:00AM	Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-22-24 04:31PM	Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
Mar-29-24 11:30AM	Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report? (Zacks)
Mar-07-24 03:31AM	1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right. (Motley Fool)
Mar-05-24 11:52PM	Insider Sells Shares of Editas Medicine Inc (EDIT) (GuruFocus.com) -7.86%
Mar-04-24 10:30AM	1 Beaten-Down Stock With 55% Upside, According to Wall Street (Motley Fool) -5.79%
Mar-02-24 09:49PM	Why Editas Medicine Stock Soared as Much as 42% Higher This Week (Motley Fool)
Feb-29-24 11:26AM	Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Call Transcript (Insider Monkey) -9.12%
08:42AM	Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up (Zacks)
Feb-28-24 11:15PM	Q4 2023 Editas Medicine Inc Earnings Call (Thomson Reuters StreetEvents) +24.94%
08:10AM	Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:35AM	Editas Medicine Inc (EDIT) Reports Improved Financials and Advances in Gene Editing Trials (GuruFocus.com)
07:08AM	Editas: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates (GlobeNewswire)
Feb-21-24 07:00AM	Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events (GlobeNewswire)
Feb-19-24 09:55AM	Wall Street Analysts Believe Editas (EDIT) Could Rally 80%: Here's is How to Trade (Zacks)
Feb-10-24 05:09PM	Top 11 CRISPR Stocks To Invest In (Insider Monkey)
Feb-06-24 12:00PM	What Makes Editas (EDIT) a New Buy Stock (Zacks)
Jan-31-24 09:00AM	Editas Medicine to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-28-24 08:45AM	2 Under-the-Radar Stocks With Incredible Upside Potential (Motley Fool)
Jan-21-24 09:37AM	Could Editas Medicine Become the Next CRISPR Therapeutics? (Motley Fool)
Jan-17-24 12:04PM	7 Mighty Healthcare Stocks Changing the Game of Medicine (InvestorPlace)
Jan-15-24 05:19AM	Down 88%, Could Editas Medicine Be a Good Investment Now? (Motley Fool)
Jan-11-24 04:38PM	3 Stocks to Buy in the Booming Field of Gene Editing (InvestorPlace)
Jan-08-24 08:15AM	Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference (GlobeNewswire)
07:45AM	Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics (Motley Fool)

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lucera Erick	EVP, CHIEF FINANCIAL OFFICER	Mar 04 '25	Sale	1.71	4,109	7,030	112,720	Mar 05 04:44 PM
O'Neill Gilmore Neil	CEO	Mar 04 '25	Sale	1.71	16,632	28,452	295,474	Mar 05 04:43 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Mar 04 '25	Sale	1.71	2,891	4,946	70,245	Mar 05 04:41 PM
O'Neill Gilmore Neil	Officer	Mar 03 '25	Proposed Sale	1.86	35,000	65,100		Feb 28 04:40 PM
Lucera Erick	Officer	Mar 03 '25	Proposed Sale	1.86	8,000	14,880		Feb 28 04:39 PM
Burkly Linda	Officer	Mar 03 '25	Proposed Sale	1.86	6,000	11,160		Feb 28 04:35 PM
O'Neill Gilmore Neil	CEO	Dec 03 '24	Sale	2.08	1,618	3,361	312,106	Dec 05 04:40 PM
Mei Baisong	EVP, CHIEF MEDICAL OFFICER	Dec 03 '24	Sale	2.08	541	1,124	133,354	Dec 05 04:37 PM
Mei Baisong	EVP, CHIEF MEDICAL OFFICER	Sep 04 '24	Sale	3.42	518	1,774	133,895	Sep 06 04:20 PM
O'Neill Gilmore Neil	CEO	Sep 04 '24	Sale	3.42	1,555	5,325	313,724	Sep 06 04:18 PM
O'Neill Gilmore Neil	Officer	Sep 03 '24	Proposed Sale	3.92	3,000	11,760		Aug 29 04:19 PM
Mei Baisong	Officer	Sep 03 '24	Proposed Sale	3.92	1,000	3,920		Aug 29 04:17 PM
Burkly Linda	EVP, CHIEF SCIENTIFIC OFFICER	Jul 25 '24	Sale	5.42	11,886	64,370	73,136	Jul 26 05:02 PM
Mei Baisong	EVP, CHIEF MEDICAL OFFICER	Jul 19 '24	Sale	5.21	6,619	34,456	134,413	Jul 22 05:01 PM
O'Neill Gilmore Neil	CEO	Jun 04 '24	Sale	5.50	12,191	66,997	315,279	Jun 06 04:17 PM
Mei Baisong	EVP, CHIEF MEDICAL OFFICER	Jun 04 '24	Sale	5.50	511	2,808	141,032	Jun 06 04:16 PM
Lucera Erick	EVP, CHIEF FINANCIAL OFFICER	May 20 '24	Sale	5.61	22,337	125,404	116,829	May 22 04:30 PM
Hopfield Jessica	Director	May 13 '24	Buy	5.64	45,000	253,868	67,700	May 14 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EDIT

Editas Medicine Inc

Upgrade your FINVIZ experience